Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: A single-centre, open-label, randomised controlled trial

BMJ Open

Volumn 6, Issue 12, 2016, Pages

  Hagiwara, Akiyoshi ^a   Tanaka, Noriko ^a   Uemura, Tatsuki ^a   Matsuda, Wataru ^a   Kimura, Akio ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

C reactive protein; D dimer; disseminated intravascular coagulation; recombinant human thrombomodulin; sepsis; survival

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; C REACTIVE PROTEIN; D DIMER; RECOMBINANT HUMAN THROMBOMODULIN; THROMBOMODULIN; UNCLASSIFIED DRUG; THBD PROTEIN, HUMAN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL RATE; TERTIARY CARE CENTER; THROMBOCYTE COUNT; ADULT; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; HOSPITAL MORTALITY; JAPAN; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ORGAN DYSFUNCTION SCORE; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTICOAGULANTS; DISSEMINATED INTRAVASCULAR COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOSPITAL MORTALITY; HUMANS; JAPAN; MALE; MIDDLE AGED; ORGAN DYSFUNCTION SCORES; PROSPECTIVE STUDIES; SEPSIS; SURVIVAL RATE; THROMBOMODULIN; TREATMENT OUTCOME;

EID: 85008487988     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-012850     Document Type: Article

References (16)

1. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005;131:417-30.
2. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005;115:1267-74.
3. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007;5:31-41.
4. Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009;145:24-33.
5. Yamakawa K, Fujimi S, Mohri T, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care 2011;15:R123.
6. Ogawa Y, Yamakawa K, Ogura H, et al. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg 2012;72:1150-7.
7. Yamakawa K, Ogura H, Fujimi S, et al. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med 2013;39:644-52.
8. Vincent JL, Ramesh MK, Ernest D, et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013;41:2069-79.
9. Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006;34:625-31.
10. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
11. MacIntyre NR, Cook DJ, Ely EW Jr, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest 2001;120(6 Suppl):375S-95S.
12. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013;48:452-8.
13. Kato T, Sakai T, Kato M, et al. Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thromb J 2013;11:3.
14. Yoshimura J, Yamakawa K, Ogura H, et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care 2015;19:78.
15. Aikawa N, Shimazaki S, Yamamoto Y, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock 2011;35:349-54.
16. Murata A, Okamoto K, Mayumi T, et al. Recent change in treatment of disseminated intravascular coagulation in Japan: an epidemiological study based on a national administrative database. Clin Appl Thromb Hemost 2016;22:21-7.